Genvoya

Genvoya is a combination medication used in the treatment of HIV-1 infection. It contains four active ingredients: emtricitabine, tenofovir alafenamide, cobicistat, and elvitegravir. This oral medication is designed to help manage HIV by reducing the amount of virus in the body.

Genvoya is primarily used for the treatment of HIV-1 infection in adults and children who weigh at least 25 kg. It is a combination antiretroviral therapy that works by reducing the amount of HIV in the body, helping to control the infection. Genvoya is not a cure for HIV or AIDS, but it can help people with HIV live longer, healthier lives. It is often used as part of a comprehensive treatment plan that includes other medications and lifestyle changes.

Common effects of Genvoya may include nausea, diarrhea, headache, and fatigue. Some people may also experience changes in body fat, such as increased weight in the upper back, neck, or around the middle of the body. These effects are generally mild and go away over time, but if they become severe or persistent, it is important to consult a healthcare provider.

Genvoya should be used with caution in people with kidney problems, as it can affect kidney function. It is also important to monitor liver function regularly while taking this medication, as it can cause liver problems in some people. Genvoya should not be used by people who are allergic to any of its ingredients or who have severe liver problems. It is important to follow the dosage instructions provided by a healthcare provider and to take the medication exactly as prescribed.

Genvoya can interact with a number of other medications, including certain antibiotics, antifungals, and seizure medications. It is important to tell a healthcare provider about all medications being taken, including prescription and over-the-counter drugs, vitamins, and herbal supplements. Alcohol should be avoided while taking Genvoya, as it can increase the risk of side effects. It is also important to avoid taking Genvoya with other medications that contain tenofovir disoproxil fumarate, as this can increase the risk of kidney problems.